Overview

A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to estimate the time from the first dose of LY573636-sodium (hereafter referred to as LY573636) to the date your physician determines that your disease has progressed or worsened.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company